In patients with prostate cancer, prior research has shown that germline BRCA mutations have a negative effect on outcomes. However, the connection between somatic and germline mutations in homologous recombination repair (HRR) genes and treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. A study from David Olmos, MD, PhD, and Elena Castro, MD, PhD, sought to determine the outcomes and prevalence related to somatic or germline HRR alterations, specifically BRCA1/2, in patients beginning first-line treatment with androgen receptor signaling inhibitors or taxanes for mCRPC. ...
CRPC
Advertisement
Latest News
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
OS was compared using Cox proportional hazards models with IPTW adjusted for baseline characteristics.
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Dr. George delves into research for HRR mutation testing in mCRPC, including strategies for earlier testing after diagnosis.
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
